laura esserman
laura esserman
Professor of Surgery and Radiology, University of California, San Francisco
Verified email at
Cited by
Cited by
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies
K Chin, S DeVries, J Fridlyand, PT Spellman, R Roydasgupta, WL Kuo, ...
Cancer cell 10 (6), 529-541, 2006
Whole-genome analysis informs breast cancer response to aromatase inhibition
MJ Ellis, LI Ding, D Shen, J Luo, VJ Suman, JW Wallis, BA Van Tine, ...
Nature 486 (7403), 353-360, 2012
Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A …
JS Vaidya, F Wenz, M Bulsara, JS Tobias, DJ Joseph, M Keshtgar, ...
The Lancet 383 (9917), 603-613, 2014
Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial
JS Vaidya, DJ Joseph, JS Tobias, M Bulsara, F Wenz, C Saunders, ...
The Lancet 376 (9735), 91-102, 2010
Rethinking screening for breast cancer and prostate cancer
L Esserman, Y Shieh, I Thompson
Jama 302 (15), 1685-1692, 2009
Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update.
JL Khatcheressian, P Hurley, E Bantug, LJ Esserman, E Grunfeld, ...
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer
C Hatzis, L Pusztai, V Valero, DJ Booser, L Esserman, A Lluch, T Vidaurre, ...
Jama 305 (18), 1873-1881, 2011
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor–rich stage 2 to 3 breast cancer …
MJ Ellis, VJ Suman, J Hoog, L Lin, J Snider, A Prat, JS Parker, J Luo, ...
Journal of Clinical Oncology 29 (17), 2342, 2011
Overdiagnosis and overtreatment in cancer: an opportunity for improvement
LJ Esserman, IM Thompson, B Reid
Jama 310 (8), 797-798, 2013
Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging
L Esserman, N Hylton, L Yassa, J Barclay, S Frankel, E Sickles
Journal of clinical oncology 17 (1), 110-110, 1999
Adaptive randomization of veliparib–carboplatin treatment in breast cancer
HS Rugo, OI Olopade, A DeMichele, C Yau, LJ van’t Veer, MB Buxton, ...
New England Journal of Medicine 375 (1), 23-34, 2016
Addressing overdiagnosis and overtreatment in cancer: a prescription for change
LJ Esserman, IM Thompson, B Reid, P Nelson, DF Ransohoff, HG Welch, ...
The lancet oncology 15 (6), e234-e242, 2014
Leukocyte composition of human breast cancer
B Ruffell, A Au, HS Rugo, LJ Esserman, ES Hwang, LM Coussens
Proceedings of the National Academy of Sciences 109 (8), 2796-2801, 2012
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657
LJ Esserman, DA Berry, A DeMichele, L Carey, SE Davis, M Buxton, ...
Journal of Clinical Oncology 30 (26), 3242, 2012
Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy—results from ACRIN 6657/I-SPY TRIAL
NM Hylton, JD Blume, WK Bernreuter, ED Pisano, MA Rosen, EA Morris, ...
Radiology 263 (3), 663, 2012
Breast cancer growth prevention by statins
MJ Campbell, LJ Esserman, Y Zhou, M Shoemaker, M Lobo, E Borman, ...
Cancer research 66 (17), 8707-8714, 2006
Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy
SC Partridge, JE Gibbs, Y Lu, LJ Esserman, D Sudilovsky, NM Hylton
American Journal of Roentgenology 179 (5), 1193-1199, 2002
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
LJ Esserman, DA Berry, MCU Cheang, C Yau, CM Perou, L Carey, ...
Breast cancer research and treatment 132 (3), 1049-1062, 2012
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
D Horiuchi, L Kusdra, NE Huskey, S Chandriani, ME Lenburg, ...
Journal of Experimental Medicine 209 (4), 679-696, 2012
Ductal lavage for detection of cellular atypia in women at high risk for breast cancer
WC Dooley, BM Ljung, U Veronesi, M Cazzaniga, RM Elledge, ...
Journal of the national cancer institute 93 (21), 1624-1632, 2001
The system can't perform the operation now. Try again later.
Articles 1–20